Immunological responses to oxidized LDL

Free Radical Biology and Medicine

Volumn 28, Issue 12, 2000, Pages 1771-1779

  Hörkkö, Sohvi ^a   Binder, Christoph J ^a   Shaw, Peter X ^a   Chang, Mi Kyung ^a   Silverman, Gregg ^a   Palinski, Wulf ^a   Witztum, Joseph L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Autoantibodies; Free radical; Immunity; Immunoglobulins; Oxidized LDL; Oxidized phospholipids; T cells

Indexed keywords

4 HYDROXYNONENAL; AUTOANTIBODY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; LOW DENSITY LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MALONALDEHYDE; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; RECEPTOR;

APOPTOSIS; ATHEROSCLEROSIS; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW;

EID: 0343602817     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(00)00333-6     Document Type: Article

References (71)

1. Steinberg D., Witztum J.L. Lipoproteins, lipoprotein oxidation, and atherogenesis. Chien, K. 1999;458-475 W. B. Saunders Co, R. Molecular basis of cardiovascular disease. Philadelphia.
2. Newby, A. C.; Libby, P.; van der Wal A. C. Plaque instability - the real challenge for atherosclerosis research in the next decade? [editorial]. Cardiovasc. Res. 41:321-322; 1999.
3. Libby P., Hansson G.K., Pober J.S. Atherogenesis and inflammation. Chien, K. 1999;349-366 W. B. Saunders, R. Molecular basis of cardiovascular disease. Philadelphia.
4. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
5. Hansson G.K. Cell-mediated immunity in atherosclerosis. Curr. Opin. Lipidol. 8:1997;301-311.
6. Witztum J.L., Palinski W. Are immunological mechanisms relevant for the development of atherosclerosis? [editorial]. Clin. Immunol. 90:1999;153-156.
7. Abraham R., Choudhury A., Basu S.K., Bal V., Rath S. Disruption of T cell tolerance by directing a self antigen to macrophage-specific scavenger receptors. J. Immunol. 158:1997;4029-4035.
8. Singh N., Bhatia S., Abraham R., Basu S.K., George A., Bal V., Rath S. Modulation of T cell cytokine profiles and peptide-MHC complex availability in vivo by delivery to scavenger receptors via antigen maleylation. J. Immunol. 160:1998;4869-4880.
9. Mach F., Schönbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.Y., Pober J.S., Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages implications for CD40-CD40 ligand signaling in atherosclerosis . Proc. Natl. Acad. Sci. USA. 94:1997;1931-1936.
10. Meliaan A., Geng Y.J., Sukhova G.K., Libby P., Porcelli S.A. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am. J. Path. 155:1999;775-786.
11. Zhou X., Hansson G.K. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scand. J. Immunol. 50:1999;25-30.
12. Sohma Y., Sasano H., Shiga R., Saeki S., Suzuki T., Nagura H., Nose M., Yamamoto T. Accumulation of plasma cells in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Proc. Natl. Acad. Sci. USA. 92:1995;4937-4941.
13. Roselaar S.E., Schonfeld G., Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J. Clin. Invest. 96:1995;1389-1394.
14. Fyfe A.I., Qiao J.H., Lusis A.J. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J. Clin. Invest. 94:1994;2516-2520.
15. Mach F., Schönbeck U., Sukhova G.K., Atkinson E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 394:1998;200-203.
16. Nicoletti A., Kaveri S., Caligiuri G., Bariety J., Hansson G.K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 102:1998;910-918.
17. Palinski W., Miller E., Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA. 92:1995;821-825.
18. Freigang S., Hörkkö S., Miller E., Witztum J.L., Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18:1998;1972-1982.
19. Ameli S., Hultgeardh-Nilsson A., Regnström J., Calara F., Yano J., Cercek B., Shah P.K., Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16:1996;1074-1079.
20. Nilsson J., Calara F., Regnström J., Hultgardh-Nilsson A., Ameli S., Cercek B., Shah P.K. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J. Am. Coll. Cardiol. 30:1997;1886-1891.
21. George J., Afek A., Gilburd B., Levkovitz H., Shaish A., Goldberg I., Kopolovic Y., Wick G., Shoenfeld Y., Harats D. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis. 138:1998;147-152.
22. Xu Q., Dietrich H., Steiner H.J., Gown A.M., Schoel B., Mikuz G., Kaufmann S.H., Wick G. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12:1992;789-799.
23. George J., Shoenfeld Y., Afek A., Gilburd B., Keren P., Shaish A., Kopolovic J., Wick G., Harats D. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler. Thromb. Vasc. Biol. 19:1999;505-510.
24. Dansky H.M., Charlton S.A., Harper M.M., Smith J.D. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 94:1997;4642-4646.
25. Daugherty A., Puré E., Delfel-Butteiger D., Chen S., Leferovich J., Roselaar S.E., Rader D.J. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J. Clin. Invest. 100:1997;1575-1580.
26. Libby P., Egan D., Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis an assessment of the evidence and need for future research . Circulation. 96:1997;4095-4103.
27. Wick G., Perschinka H., Xu Q. Autoimmunity and atherosclerosis. Am. Heart J. 138:1999;S444-S449.
28. Palinski W., Koschinsky T., Butler S.W., Miller E., Vlassara H., Cerami A., Witztum J.L. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler. Thromb. Vasc. Biol. 15:1995;571-582.
29. Reaven P., Merat S., Casanada F., Sutphin M., Palinski W. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 17:1997;2250-2256.
30. Paulsson G., Zhou X., Torrielli M., Hansson G.K. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient nice. Arterioscler. Thromb. Vasc. Biol. 20:2000;10-17.
31. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA. 92:1995;3893-3897.
32. Witztum J.L., Steinbrecher U.P., Kesäniemi Y.A., Fisher M. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc. Natl. Acad. Sci. USA. 81:1984;3204-3208.
33. Steinbrecher U.P., Fisher M., Witztum J.L., Curtiss L.K. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation generation of antibodies specific for derivatized lysine . J. Lipid Res. 25:1984;1109-1116.
34. Palinski W., Rosenfeld M.E., Ylä-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., Witztum J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1989;1372-1376.
35. Palinski W., Ylä-Herttuala S., Rosenfeld M.E., Butler S.W., Socher S.A., Parthasarathy S., Curtiss L.K., Witztum J.L. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 10:1990;325-335.
36. Hörkkö S., Miller E., Dudl E., Reaven P., Curtiss L.K., Zvaifler N.J., Terkeltaub R., Pierangeli S.S., Branch D.W., Palinski W., Witztum J.L. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J. Clin. Invest. 98:1996;815-825.
37. Hörkkö S., Miller E., Branch D.W., Palinski W., Witztum J.L. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc. Natl. Acad. Sci. USA. 94:1997;10356-10361.
38. Fong L.G., Parthasarathy S., Witztum J.L., Steinberg D. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J. Lipid Res. 28:1987;1466-1477.
39. Rosenfeld M.E., Palinski W., Ylä-Herttuala S., Butler S., Witztum J.L. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:1990;336-349.
40. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde- lysine in serum. Arterioscler. Thromb. 14:1994;605-616.
41. Ylä-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086-1095.
42. Ylä-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14:1994;32-40.
43. Palinski W., Tangirala R.K., Miller E., Young S.G., Witztum J.L. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15:1995;1569-1576.
44. Reaven P.D., Napoli C., Merat S., Witztum J.L. Lipoprotein modification and atherosclerosis in aging. Exp. Gerentol. 34:2000;527-537.
45. Cyrus T., Witztum J.L., Rader D.J., Tangirala R., Fazio S., Linton M.F., Funk C.D. Disruption of the 12/15 lipoxygenase gene diminishes atherosclerosis in apolipoprotein E-deficient mice. J. Clin. Invest. 103:1999;1597-1604.
46. Salonen J.T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssönen K., Palinski W., Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
47. Palinski W., Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atheroscleosis. J. Intern. Med. 247:2000;371-380.
48. Ylä-Herttuala S. Is oxidized low-density lipoprotein present in vivo? Curr. Opin. Lipidol. 9:1998;337-344.
49. Palinski W., Hörkkö S., Miller E., Steinbrecher U.P., Powell H.C., Curtiss L.K., Witztum J.L. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98:1996;800-814.
50. Hörkkö S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J.A., Friedman P., Dennis E.A., Curtiss L.K., Palinski W., Witztum J.L. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103:1999;117-128.
51. Bird D.A., Gillotte K.L., Hörkkö S., Friedman P., Dennis E.A., Witztum J.L., Steinberg D. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties implications with respect to macrophage recognition of apoptotic cells . Proc. Natl. Acad. Sci. USA. 96:1999;6347-6352.
52. Wiklund O., Witztum J.L., Carew T.E., Pittman R.C., Elam R.L., Steinberg D. Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits. J. Lipid Res. 28:1987;1098-1109.
53. Khoo J.C., Miller E., Pio F., Steinberg D., Witztum J.L. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler. Thromb. 12:1992;1258-1266.
54. Sambrano G.R., Steinberg D. Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages role of membrane phosphatidylserine . Proc. Natl. Acad. Sci. USA. 92:1995;1396-1400.
55. Chang M., Bergmark C., Laurila A., Hörkkö S., Han K.H., Friedman P., Dennis E.A., Witztum J.L. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages evidence that oxidation-specific epitopes mediate macrophage recognition . Proc. Natl. Acad. Sci. USA. 96:1999;6353-6358.
56. Branch D.W., Mitchell M.D., Miller E., Palinski W., Witztum J.L. Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein [see comments]. Lancet. 343:1994;645-646.
57. Deguchi H., Fernandez J.A., Hackeng T.M., Banka C.L., Griffin J.H. Cardiolipin is a normal component of human plasma lipoproteins. Proc. Natl. Acad. Sci. USA. 97:2000;1743-1748.
58. Iuliano L., Praticò D., Ferro D., Pittoni V., Valesini G., Lawson J., FitzGerald G.A., Violi F. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood. 90:1997;3931-3935.
59. Praticò D., Ferro D., Iuliano L., Rokach J., Conti F., Valesini G., FitzGerald G.A., Violi F. Ongoing prothrombotic state in patients with antiphospholipid antibodies a role for increased lipid peroxidation . Blood. 93:1999;3401-3407.
60. Vaarala O., Mänttäri M., Manninen V., Tenkanen L., Puurunen M., Aho K., Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 91:1995;23-27.
61. Wu R., Nityanand S., Berglund L., Lithell H., Holm G., Lefvert A.K. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 17:1997;3159-3163.
62. Liblau R.S., Singer S.M., McDevitt H.O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today. 16:1995;34-38.
63. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
64. Zhou X., Paulsson G., Stemme S., Hansson G.K. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101:1998;1717-1725.
65. Lee T.S., Yen H.C., Pan C.C., Chau L.Y. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:1999;734-742.
66. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99:1997;2752-2761.
67. Nagano H., Mitchell R.N., Taylor M.K., Hasegawa S., Tilney N.L., Libby P. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J. Clin. Invest. 100:1997;550-557.
68. Mallat Z., Besnard S., Duriez M., Deleuze V., Emmanuel F., Bureau M.F., Soubrier F., Esposito B., Duez H., Fievet C., Staels B., Duverger N., Scherman D., Tedgui A. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85:1999;e17-e24.
69. Pinderski Oslund L.J., Hedrick C.C., Olvera T., Hagenbaugh A., Territo M., Berliner J.A., Fyfe A.I. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19:1999;2847-2853.
70. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1993;1041-1048.
71. Uyemura K., Demer L.L., Castle S.C., Jullien D., Berliner J.A., Gately M.K., Warrier R.R., Pham N., Fogelman A.M., Modlin R.L. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. 97:1996;2130-2138.